These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30487792)

  • 1. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
    Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
    Front Immunol; 2018; 9():2587. PubMed ID: 30487792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
    Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
    Almeida JS; Couceiro P; López-Sejas N; Alves V; Růžičková L; Tarazona R; Solana R; Freitas-Tavares P; Santos-Rosa M; Rodrigues-Santos P
    Front Immunol; 2019; 10():2493. PubMed ID: 31695700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function.
    Damele L; Montaldo E; Moretta L; Vitale C; Mingari MC
    Front Immunol; 2018; 9():2433. PubMed ID: 30405627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
    Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
    Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic myeloid leukemia and NK cell immunity].
    Ureshino H; Shindo T; Tanaka H; Kimura S
    Rinsho Ketsueki; 2017; 58(4):381-388. PubMed ID: 28484170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allelic polymorphisms of
    Shindo T; Ureshino H; Kojima H; Tanaka H; Kimura S
    Immunol Med; 2021 Jun; 44(2):61-68. PubMed ID: 32715973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia.
    Izumi K; Shindo T; Ngo HT; Nakayama-Hosoya K; Akahane K; Tamai M; Nguyen TTT; Kawana-Tachikawa A; Inukai T; Takaori-Kondo A
    Immunohorizons; 2021 Aug; 5(8):687-702. PubMed ID: 34433624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
    Pierson BA; Miller JS
    Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia.
    Chang YC; Chiang YH; Hsu K; Chuang CK; Kao CW; Chang YF; Chang MC; Lim KH; Cheng HI; Hsu YN; Chen CG
    Blood Cancer J; 2021 Nov; 11(11):182. PubMed ID: 34785653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors.
    Hong Y; Wen R; Wu G; Li S; Liu W; Chen Z; Yang Z
    Int Immunopharmacol; 2022 Aug; 109():108821. PubMed ID: 35526383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
    Kumagai T
    Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Ureshino H; Shindo T; Tanaka H; Saji H; Kimura S
    Mol Cancer Ther; 2021 Jan; 20(1):142-149. PubMed ID: 33082274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Hus I; Tabarkiewicz J; Lewandowska M; Wasiak M; Wdowiak P; Kusz M; Legieć M; Dmoszyńska A; Roliński J
    Folia Histochem Cytobiol; 2011; 49(1):153-60. PubMed ID: 21526503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-free remission and immunity in chronic myeloid leukemia.
    Ureshino H
    Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
    Ilander M; Olsson-Strömberg U; Schlums H; Guilhot J; Brück O; Lähteenmäki H; Kasanen T; Koskenvesa P; Söderlund S; Höglund M; Markevärn B; Själander A; Lotfi K; Dreimane A; Lübking A; Holm E; Björeman M; Lehmann S; Stenke L; Ohm L; Gedde-Dahl T; Majeed W; Ehrencrona H; Koskela S; Saussele S; Mahon FX; Porkka K; Hjorth-Hansen H; Bryceson YT; Richter J; Mustjoki S
    Leukemia; 2017 May; 31(5):1108-1116. PubMed ID: 27890936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission.
    Dumas PY; Bérard E; Bréal C; Dulucq S; Réa D; Nicolini F; Forcade E; Dufossée M; Pasquet JM; Turcq B; Bidet A; Milpied N; Déchanet-Merville J; Lafarge X; Etienne G; Mahon FX;
    Cancer Med; 2019 Sep; 8(11):4976-4985. PubMed ID: 31287239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.